GlycoMimetics, Inc. (GLYC) Covered Calls

You can sell covered calls on GlycoMimetics, Inc. to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for GLYC (prices last updated Wed 4:16 PM ET):

GlycoMimetics, Inc. (GLYC) Stock Quote
Last Change Bid Ask Volume P/E Market Cap
2.28 +0.13 2.25 2.49 843K - 0.1
Covered Calls For GlycoMimetics, Inc. (GLYC)
Expiration Strike Call Bid Net Debit Return
If Flat
Return If Flat
Apr 19 2.5 0.00 2.49 0.0% 0.0%
May 17 2.5 0.80 1.69 47.3% 557%
Subscribers get access to the full covered call chain, and more features.

Want to make money with covered calls?  Sign Up For A Free Trial

Extended Business Description

GlycoMimetics, Inc., a clinical stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. Its advanced drug candidate, rivipansel, is a pan-selectin antagonist, which is developed for the treatment of vaso-occlusive crisis in sickle cell disease and has evaluated in a Phase 3 clinical trial, conducted by its strategic collaboration with Pfizer Inc. The company's drug candidate, GMI-1271, an E-selectin antagonist, is evaluated in a Phase 1/2 clinical trial as a potential treatment for acute myeloid leukemia and is in a Phase 1 clinical trial for the treatment of multiple myeloma. It is also developing a Phase 1 clinical trial drug candidate, GMI-1359, a combined CXCR4 and E-selectin antagonist. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland